How to approach drug-eluting stent restenosis

P. Roy, R. Waksman*

*Corresponding author for this work

    Research output: Contribution to journalReview articlepeer-review


    Drug-eluting stents (DES) have been a major advance in percutaneous coronary intervention reducing restenosis and repeat revascularization. The application of DES to the treatment of complex lesion and patient subsets has resulted in significant rates of DES restenosis or failure. Though predominantly focal, substantial rates of non-focal DES restenosis are being observed. Non-focal disease most likely represents a resistant process that will remain a therapeutic challenge. An understanding of the causative mechanical and biological factors is essential for the prevention and treatment of DES restenosis. Robust data relating to the treatment efficacy for this problem is lacking. At present, repeat DES or vascular brachytherapy appear to the best available options. Evidence from randomized controlled trials and large registries is required to establish a formal treatment approach. We provide guidelines based on current available evidence.

    Original languageEnglish
    Pages (from-to)571-576
    Number of pages6
    JournalMinerva Cardioangiologica
    Issue number5
    Publication statusPublished - Oct 2006


    • Coronary artery disease
    • Drug-eluting stents
    • Restenosis


    Dive into the research topics of 'How to approach drug-eluting stent restenosis'. Together they form a unique fingerprint.

    Cite this